From the Journals

Understanding Protocol AO, the DRCR Retina Network’s Study of Home OCT

A conversation with Christina Y. Weng, MD, MBA

Share

The conversation with Christina Y. Weng, MD, MBA focuses on the potential effectiveness of home optical coherence tomography (OCT) in monitoring the progression of neovascular age-related macular degeneration (nAMD). Dr. Weng outlines its advantages, including the potential for personalized care, earlier disease detection, and better outcomes for patients. The discussion addresses challenges in implementation, patient adherence, potential financial implications, and the choice of faricimab in Protocol AO.

Original Source(s)

Understanding Protocol AO, the DRCR Retina Network’s Study of Home OCT

A conversation with Christina Y. Weng, MD, MBA

  • by Christina Y. Weng, MD, MBA, Jim Gallagher, senior managing editor

  • January 1, 2025

  • 11 min

Related Content

PRISM Trial Update Presented at RWC

Mark Barakat, MD, provided an update on the PRISM clinical trial for 4D-150 (4DMT) for wet AMD at the Retina World Congress meeting in Fort Lauderdale.

Real-World nAMD Treatment Patterns Reveal Cost of Switching

Analysis of Medicare claims show increases in drug-related expenditures after initial low-cost therapy.

Migaldendranib May Move the Needle in AMD, DME

Michael A. Singer, MD, shares early phase 2 data supporting D-4517.2 as a safe and effective subcutaneous therapy, reducing injection burden and preserving vision.